Excelestar Ventures — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
Instylla develops resorbable liquid embolic agents for interventional radiology and oncology, including the Embrace Hydrogel Embolic System and the Tembo Embolic System used to embolize hypervascular tumors and occlude peripheral blood vessels.
BiotechHealthtechMedical DevicesBedford, US
Amarpreet Sawhney(Executive Officer)Raymond Lareau(Executive Officer)Steven Cagnetta(Executive Officer)Sean Boyle(Chief Executive Officer)
BoardHenry Chen(Director)in
Board seatTasneem Dohadwala· per SEC Form D
Co-investorsAngel Physicians FundAscension VenturesDelos Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.